Patents Assigned to Vitae Pharmaceuticals, LLC
-
Publication number: 20240124447Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: ApplicationFiled: May 18, 2023Publication date: April 18, 2024Applicant: Vitae Pharmaceuticals, LLCInventors: Salvacion CACATIAN, David A. CLAREMON, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG
-
Patent number: 11919901Abstract: The present disclosure is directed to inhibitors of Formula (0), or a stereoisomer thereof, or pharmaceutically acceptable salt thereof, of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction,Type: GrantFiled: May 13, 2022Date of Patent: March 5, 2024Assignees: Syndax Pharmaceuticals, Inc., Vitae Pharmaceuticals, LLCInventors: Gerard M. McGeehan, William H. Miller, Nicholas Paul Camp, Salvacion Cacatian, Santosh S. Kulkarni, Swapan Kumar Samanta, Virsinha Venkat Reddy
-
Patent number: 11739085Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: GrantFiled: August 11, 2020Date of Patent: August 29, 2023Assignee: Vitae Pharmaceuticals, LLCInventors: Salvacion Cacatian, David A. Claremon, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang
-
Patent number: 11535614Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: September 9, 2020Date of Patent: December 27, 2022Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 11479557Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: GrantFiled: April 1, 2020Date of Patent: October 25, 2022Assignee: VITAE PHARMACEUTICALS, LLCInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
-
Patent number: 11186573Abstract: The present disclosure relates to salts and crystalline forms of a compound having the formula (I): Also described are processes for the production of the salts and crystalline forms described herein.Type: GrantFiled: July 24, 2018Date of Patent: November 30, 2021Assignee: Vitae Pharmaceuticals, LLCInventors: Chaoyi Deng, Jun He, Bo Xu
-
Publication number: 20210179611Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: ApplicationFiled: August 11, 2020Publication date: June 17, 2021Applicant: Vitae Pharmaceuticals, LLCInventors: Salvacion CACATIAN, David A. CLAREMON, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG
-
Patent number: 11008340Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: November 17, 2016Date of Patent: May 18, 2021Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
-
Patent number: 11001583Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: April 25, 2019Date of Patent: May 11, 2021Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Linghang Zhuang
-
Publication number: 20210053974Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: ApplicationFiled: April 1, 2020Publication date: February 25, 2021Applicant: VITAE PHARMACEUTICALS, LLCInventors: Salvacion CACATIAN, David A. CLAREMON, Lawrence Wayne DILLARD, Chengguo DONG, Yi FAN, Lanqi JIA, Stephen D. LOTESTA, Andrew MARCUS, Angel MORALES-RAMOS, Suresh B. SINGH, Shankar VENKATRAMAN, Jing YUAN, Yajun ZHENG, Linghang ZHUANG, Stephan D. PARENT, Travis L. HOUSTON
-
Patent number: 10913739Abstract: The present disclosure relates to processes for the production of salts and crystalline forms of a compound having the formula.Type: GrantFiled: July 24, 2018Date of Patent: February 9, 2021Assignee: Vitae Pharmaceuticals, LLC (121374)Inventors: Robert J. Duguid, John A. Grosso, Sergiy Krasutsky
-
Patent number: 10899758Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: GrantFiled: September 15, 2017Date of Patent: January 26, 2021Assignee: VITAE PHARMACEUTICALS, LLCInventors: Salvacion Cacatian, David A. Claremon, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang
-
Patent number: 10829481Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: January 27, 2017Date of Patent: November 10, 2020Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Linghang Zhuang
-
Patent number: 10829448Abstract: Provided are indole, benzoimidazole, pyrrolopyridine, and imidazopyridine derivatives and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Such derivatives include e.g., those having the Formula II: as well as pharmaceutically acceptable salts thereof. The disclosed derivatives may be used for treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: April 3, 2019Date of Patent: November 10, 2020Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Linghang Zhuang
-
Patent number: 10807980Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: July 9, 2019Date of Patent: October 20, 2020Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 10683302Abstract: The present invention is directed to inhibitors of the interaction of menin with MLL and MLL fusion proteins, pharmaceutical compositions containing the same, and their use in the treatment of cancer and other diseases mediated by the menin-MLL interaction.Type: GrantFiled: June 8, 2017Date of Patent: June 16, 2020Assignee: VITAE PHARMACEUTICALS, LLCInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Stephen D. Lotesta, Andrew Marcus, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Jing Yuan, Yajun Zheng, Linghang Zhuang, Stephan D. Parent, Travis L. Houston
-
Publication number: 20190322687Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR?. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: ApplicationFiled: November 17, 2016Publication date: October 24, 2019Applicant: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Lanqi Jia, Suresh B. Singh, Colin M. Tice, Zhenrong Xu, Jing Yuan, Linghang Zhuang
-
Patent number: 10399976Abstract: Provided are novel compounds of Formula (I): pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by ROR. Also provided are pharmaceutical compositions comprising the novel compounds of Formula (I) and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: July 2, 2018Date of Patent: September 3, 2019Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Chengguo Dong, Yi Fan, Lanqi Jia, Zhijie Liu, Stephen D. Lotesta, Andrew Marcus, Suresh B. Singh, Colin M. Tice, Jing Yuan, Wei Zhao, Yajun Zheng, Linghang Zhuang
-
Patent number: 10336717Abstract: The present invention is directed to a compound represented by the following structural formula or a pharmaceutically acceptable salt thereof. Pharmaceutical compositions and method of use of the compounds are also described.Type: GrantFiled: October 15, 2015Date of Patent: July 2, 2019Assignee: Vitae Pharmaceuticals, LLCInventors: Salvacion Cacatian, David A. Claremon, Lawrence Wayne Dillard, Klaus Fuchs, Niklas Heine, Lanqi Jia, Katerina Leftheris, Brian McKeever, Angel Morales-Ramos, Suresh B. Singh, Shankar Venkatraman, Guosheng Wu, Zhongren Wu, Zhenrong Xu, Jing Yuan, Yajun Zheng
-
Patent number: 10301261Abstract: Provided are novel compounds of Formula I: pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof, which are useful in the treatment of diseases and disorders mediated by RORy. Also provided are pharmaceutical compositions comprising the novel compounds of Formula I and methods for their use in treating one or more inflammatory, metabolic, autoimmune and other diseases or disorders.Type: GrantFiled: August 3, 2016Date of Patent: May 28, 2019Assignee: Vitae Pharmaceuticals, LLCInventors: David A. Claremon, Lawrence Wayne Dillard, Yi Fan, Stephen D. Lotesta, Suresh B. Singh, Colin M. Tice, Wei Zhao, Linghang Zhuang